Broccoli sprout extract to improve thinking and memory
A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Broccoli Sprout Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment
NA · Pusan National University Yangsan Hospital · NCT07334366
This will test whether taking broccoli sprout extract daily for 12 weeks improves thinking and memory in adults 55–85 with mild cognitive impairment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Sponsor | Pusan National University Yangsan Hospital (other) |
| Locations | 1 site (Yangsan) |
| Trial ID | NCT07334366 on ClinicalTrials.gov |
What this trial studies
This is a randomized, placebo-controlled interventional trial comparing broccoli sprout extract to an inactive placebo over 12 weeks. Participants take the extract or placebo daily and attend visits at screening, baseline (week 0), week 6, and week 12 for cognitive testing and safety checks. Investigators will track changes in cognitive function and record any side effects during the treatment period. Eligibility requires absence of dementia and ability to read Korean, with investigators able to exclude unstable medical conditions.
Who should consider this trial
Good fit: Ideal candidates are Korean-reading adults aged 55–85 with mild cognitive impairment (GDS 2–3) who do not have dementia and are medically stable.
Not a fit: People with dementia or other major neurological diseases (e.g., Parkinson's, recent stroke), uncontrolled hypertension, recent severe medical events, or those who cannot read Korean are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this could offer an accessible dietary supplement option to modestly improve or slow cognitive decline in older adults with mild impairment.
How similar studies have performed: Related work on sulforaphane-rich extracts like broccoli sprout extract has shown promising signals in small human and animal studies, but robust evidence for improving mild cognitive impairment is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: Adults aged 55-85 years (inclusive), both male and female * Global Deterioration Scale (GDS) score of 2-3: GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment * Absence of dementia according to established diagnostic criteria * Ability to read Korean Exclusion Criteria: * Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion) * Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160/100 mmHg (measured after 10 minutes of rest) * Poor glycemic control: Fasting blood glucose ≥160 mg/dL in diabetic patients * Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism * Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution * Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution * Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress * Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities * Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period * Alcohol use disorder, severe * Food allergies: Known allergic reactions to study product components * Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator
Where this trial is running
Yangsan
- Pusan National University Yangsan Hospital — Yangsan, South Korea (RECRUITING)
Study contacts
- Study coordinator: Sang Yeoup Lee, Professor, MD, PhD
- Email: drsaylee@gmail.com
- Phone: 360-2860
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cognitive Dysfunction, Cognitive Decline, cognition